CEO Paul Hudson Shares the Secrets of Sanofi's Success

Across groundbreaking medicines and vaccines, and approvals for new treatments in the pipeline, Sanofi's Q3 results reflected CEO Paul Hudson's commitment to the company's millions of patients. 

The results, announced on 24 October, show 7% sales growth, three new medicines added to its portfolio and two medicines on track to achieving what Paul says is "blockbuster status". 

In a post on LinkedIn, the CEO says: "As an R&D-driven, AI-powered biopharma company, we never lose sight of what truly drives each of us: improving people's lives."

Sanofi’s third-quarter 2025 results showcased the strength of its science-led strategy and continued commercial momentum. 

Newly launched medicines and vaccines rose 40.8%, supported by ALTUVIIIO and Ayvakit, while flagship immunology treatment Dupixent achieved a 26.2% increase to €4.2bn (US$4.88bn)  in quarterly sales – the first time it has surpassed the €4bn (US$4.65bn) mark.

Although vaccine sales declined 7.8% to €3.4bn (US$3.95bn) due to lower influenza demand, the overall picture was one of profitable, innovation-led growth. 

The quarter also reflected the impact of AI-powered data analytics that continue to enhance Sanofi’s R&D prioritisation and operational efficiency, driving smarter, faster decisions across the organisation.

Meeting full-year guidance

This performance positions Sanofi strongly to meet its full-year guidance.

The company confirmed expectations of high single-digit sales growth and a low double-digit percentage increase in business EPS for 2025, reaffirming confidence in its operational execution. 

Highlighting focused spending and focused investment in research, Paul said: “The growth momentum we saw in Q3 confirms continued sales and earnings progress and positions us well to achieve our full year guidance.”

Business operating income rose 8.5% at CER, with margins improving to 36.1%, underscoring the effectiveness of digital transformation and AI-enabled supply chain planning. 

These advances, along with smart procurement systems and digital health partnerships, are helping the company sustain growth and resilience in a challenging macroeconomic environment. 

Sanofi’s additional US$625m commitment to Sanofi Ventures - its evergreen fund investing in innovative biotech and digital health technologies - further underlines this ambition.

Momentum across portfolios

The Immunology franchise remains the standout, with Dupixent driving revenues above €4bn (US$4.65bn) for the first time. 

Pharma launches rose 57.1%, powered by rapid uptake of innovative treatments, while newly launched products overall climbed more than 40%.

At the same time, the company’s commitment to sustainability and equitable access remains central. 

Its Global Health Unit has now reached one million patients across more than 40 low and middle-income countries, contributing to a goal of treating two million by 2030. 

Through programmes such as the Insulins Valyou Savings Program in the US, Sanofi is ensuring that essential medicines remain affordable and accessible. 

Meanwhile, through the Resilient Cities, Reimagining Health initiative, Sanofi is helping develop climate-resilient healthcare systems – a reflection of its belief that long-term business performance and planetary health go hand-in-hand.

Robust pipeline

Pipeline progress added another layer of strength to Q3. Paul said in a statement: “Our pipeline delivered important milestones for patients this quarter, including the approval of new and differentiated medicines.”

Sanofi secured two regulatory approvals: Wayrilz in the US for immune thrombocytopenia and Tzield in China for delaying stage 3 type 1 diabetes.

He reported two positive phase 3 readouts, including amlitelimab for atopic dermatitis and Fluzone HD for influenza in adults over 50.

The company also made eight new regulatory submissions and began three new phase 3 trials, part of a robust pipeline that now includes 94 projects. 

In a previous press release, Sanofi said the completion of the Vigil Neuroscience acquisition strengthened its early-stage neurology pipeline, particularly in Alzheimer’s research, while the continued use of AI in trial design and molecule discovery is accelerating the path from lab to patient.

Paul added on LinkedIn: “We do this by chasing the miracles of science every day for the millions of patients who are counting on us.”